Nicotinamide adenine dinucleotide, a coenzyme critical for cellular energy metabolism that declines with age. NAD+ precursors like NMN and NR are studied as longevity interventions.

Mechanistic target of rapamycin, a key nutrient-sensing pathway that regulates cell growth and aging. Inhibiting mTOR (e.g., with rapamycin) has shown lifespan extension in multiple organisms.

A class of drugs that selectively eliminate senescent (aged, dysfunctional) cells to reduce inflammation and improve tissue function.

What is Epigenetic clock?

A biomarker based on DNA methylation patterns that estimates biological age, often more predictive of health outcomes than chronological age.

The period of life spent in good health, free from chronic diseases and disability associated with aging.

An immunosuppressant drug that inhibits the mTOR pathway. Research shows rapamycin may extend lifespan and improve age-related health outcomes in multiple species.

What is Biological age?

A measure of how well or poorly your body is functioning relative to your chronological age, assessed through biomarkers such as DNA methylation, telomere length, and blood panels.

What is Caloric restriction?

A dietary regimen that reduces calorie intake without malnutrition. Caloric restriction is one of the most studied interventions shown to extend lifespan across species.

Protective caps at the ends of chromosomes that shorten with each cell division. Telomere length is associated with aging and age-related diseases.

A state in which cells permanently stop dividing but resist death, accumulating with age and secreting inflammatory factors that damage surrounding tissue.

A second-generation epigenetic clock that predicts time to death and is considered one of the most accurate measures of biological aging.

What is Inflammaging?

Chronic, low-grade inflammation that increases with age and contributes to the development of age-related diseases including cardiovascular disease, diabetes, and neurodegeneration.

The large-scale study of proteins in biological systems. In longevity research, proteomics identifies blood protein signatures that predict biological age and disease risk.

What is Yamanaka factors?

A set of four transcription factors (Oct4, Sox2, Klf4, c-Myc) that can reprogram adult cells to a pluripotent state. Partial reprogramming with Yamanaka factors is being explored to reverse cellular aging.

Nicotinamide mononucleotide, a precursor to NAD+ that is widely studied as a supplement to boost cellular energy and combat age-related decline.

A gene-editing technology that allows precise modifications to DNA. In longevity research, CRISPR is used to study and potentially modify genes associated with aging.

A cellular housekeeping process where cells break down and recycle damaged components. Declines with age and is stimulated by fasting.

What is Intermittent fasting?

An eating pattern that cycles between periods of fasting and eating. Various protocols (16:8, 5:2) are studied for metabolic, cardiovascular, and longevity benefits.

What is Zone 2 cardio?

Low-intensity aerobic exercise performed at roughly 60–70% of maximum heart rate, primarily using the aerobic energy system. Associated with mitochondrial health and longevity.

Geographic regions identified by researchers where people consistently live longer and healthier lives than average, including Sardinia, Okinawa, and Loma Linda.

What Biogen's Acquisition Means for Immune Health

Biogen Inc. has completed its acquisition of RayThera Inc., a biotechnology company that specializes in developing small-molecule therapies for immune-related conditions. This strategic move enhances Biogen’s immunology portfolio, potentially leading to new treatments for a variety of immune-mediated diseases. The lead program from this acquisition has already entered Phase 1 development, indicating that Biogen is actively working to bring these new therapies to market.

For those interested in healthy aging, this acquisition could signal advancements in treatments that may improve immune function and overall health. A stronger immunology portfolio may benefit people dealing with chronic inflammatory conditions or autoimmune diseases, which can significantly impact quality of life as we age. Enhanced therapies could lead to better management of these conditions, ultimately contributing to a healthier, more vibrant life.

The acquisition is still in its early stages, with the lead program just beginning its first phase of clinical trials. While this is a promising step, it’s important to note that early-stage results do not guarantee future success in larger trials or regulatory approval. Biogen’s commitment to innovation in immunology reflects a broader trend in the biotechnology industry, where companies are increasingly focused on developing targeted therapies for complex health issues.

As Biogen continues to explore and develop these new therapies, individuals interested in longevity and wellness should stay informed about advancements in immunology. This could lead to new options for managing immune health, which is crucial for aging well. For more details about this acquisition and its potential implications, you can read the full announcement from GlobeNewswire.